Lakhia, Ronak http://orcid.org/0000-0002-4511-5341
Ramalingam, Harini
Chang, Chun-Mien
Cobo-Stark, Patricia http://orcid.org/0000-0002-8113-6211
Biggers, Laurence http://orcid.org/0000-0001-8514-9549
Flaten, Andrea
Alvarez, Jesus
Valencia, Tania
Wallace, Darren P. http://orcid.org/0000-0003-4616-7669
Lee, Edmund C. http://orcid.org/0000-0001-5843-247X
Patel, Vishal http://orcid.org/0000-0003-2875-4659
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK102572)
U.S. Department of Defense (W81XWH1810673)
Regulus Therapeutics
Article History
Received: 27 January 2022
Accepted: 4 August 2022
First Online: 15 August 2022
Competing interests
: V.P has patents involving anti-miR-17 for the treatment of ADPKD (16/466,752 and 15/753,865). V.P. serves as a scientific consultant for Otsuka Pharmaceuticals, Maze Therapeutics, and Regulus Therapeutics. V.P. lab has a sponsored research agreement with Regulus Therapeutics. V.P. lab also has a sponsored research agreement with Sanofi SA, Myonid Therapeutics, and Vifor pharmaceuticals, which are unrelated to this work. T.V. and E L. are employees of Regulus Therapeutics. The remaining authors declare no competing interests.